Ilia Yasny

Ilia Yasny is a seasoned professional with a diverse background in genetic engineering, protein design, structural biology, and molecular docking. With a focus on the pharmaceutical sector, Ilia currently leads a private venture fund that invests in pharma companies at various stages of development, from Proof of Concept (PoC) in vivo to Phase II clinical trials.

His expertise lies in areas such as molecular biology, biotechnology, and biochemistry, which he honed through his academic journey, including earning PhDs in Biochemistry and Biotechnology from Lomonosov Moscow State University.

Throughout his career, Ilia has held key roles in prestigious organizations, including serving as the Head of Scientific Research at EG Capital Advisors and as the CEO of Inbio Ventures. He has also been involved in scientific due diligence, venture investments, and strategic planning within the pharmaceutical and biomed startup sectors.

With a strong foundation in laboratory organization and management, Ilia has contributed significantly to the advancement of pharmaceutical Research and Development (R&D). His previous positions as a Scientific Expert at Inbio Ventures and IBC Generium, as well as roles in research at the Center for Perspective Medicinal Technologies and Algodign, have equipped him with a versatile skill set that spans across various domains of the pharmaceutical industry.

Ilia Yasny's current interests revolve around identifying investment opportunities, conducting pharmaceutical due diligence, developing clinical data plans, and leveraging his scientific expertise to drive successful outcomes in venture investments.